NICE does not recommend sorafenib for people with advanced hepatocellular carcinoma.

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life.

Sorafenib does not provide enough benefit to patients to justify its high cost, even when special considerations were applied, so NICE did not recommend it.

  • National Institute for Health and Care Excellence (NICE) accreditation logo